Tweet
Cureus
. 2022 Jul 1;14(7):e26480.
doi: 10.7759/cureus.26480. eCollection 2022 Jul.
Immune Thrombocytopenia in Previously Healthy Individuals Following SARS-CoV-2 Vaccination (COVID-19 Immunization): A Descriptive Research of 70 Instances With a Focus on Biomarkers, Predictive Outcomes, and Consequences
Kamal Sharma 1 , Smeet Patel 2 , Zeel Patel 3 , Kalpen B Patel 4 , Darshini B Shah 5 , Jinish Doshi 6 , Priyank Chokshi 7 , Chandan Sharma 8 , MohmadSabir M Amdani 9 , Ansh Parabtani 10 , Urva Benani 11 , Ashwati Konat 12
Affiliations
- PMID: 35923492
- PMCID: PMC9342832
- DOI: 10.7759/cureus.26480
Abstract
The coronavirus disease-2019 (COVID-19) pandemic is exacerbating the worldwide healthcare crisis. The pandemic has had an impact on nearly every system of our body. The Food and Drug Administration (FDA) gave immediate authorization of several vaccines to avoid critical COVID-19 outcomes following the rapid spread of the COVID-19. There have only been a few cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination-induced immune thrombocytopenia (ITP) so far. There should be enough information to identify whether some vaccination adverse effects, such as ITP, are caused by the vaccine. This study aims to determine how common ITP occurs after receiving the SARS-CoV-2 vaccine, as well as gender, age, symptoms, biomarkers, predicted outcomes, and sequelae. We looked at a number of research and compiled the best evidence of SARS-CoV-2 vaccine-induced thrombocytopenia currently available. To find the recommended reporting items, the search technique included keywords like "Immune thrombocytopenia," "COVID-19," "SARS-CoV-2," and "Vaccination." The search results were grouped using Boolean operators ("OR," "AND").
Keywords: covid-19; immune thrombocytopenia (itp); sars-cov-2; thrombosis; vaccination.